First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

GCLLSG CLL Study Grp; HOVON CLL Study Grp; Nordic CLL Study Grp; Israeli CLL Assoc; Canc Trials Ireland; Barbara Eichhorst; Carsten U. Niemann; Arnon P. Kater; Moritz Fuerstenau; Julia von Tresckow; Can Zhang; Sandra Robrecht; Michael Gregor; Gunnar Juliusson; Patrick Thornton; Philipp B. Staber; Tamar Tadmor; Vesa Lindström; Caspar da Cunha-Bang; Christof Schneider; Christian B. Poulsen; Thomas Illmer; Bjoern Schoettker; Thomas Noesslinger; Ann Janssens; Ilse Christiansen; Michael Baumann; Henrik Frederiksen; Marjolein van der Klift; Ulrich Jaeger; Maria B. L. Leys; Mels Hoogendoorn; Kourosh Lotfi; Holger Hebart; Tobias Gaska; Harry Koene; Lisbeth Enggaard; Jereon Goede; Josien C. Regelink; Anouk Widmer; Florian Simon; Nisha De Silva; Anna-Maria Fink; Jasmin Bahlo; Kirsten Fischer; Clemens-Martin Wendtner; Karl A. Kreuzer; Matthias Ritgen; Monika Brueggemann; Eugen Tausch; Mark-David Levin; Marinus van Oers; Christian Geisler; Stephan Stilgenbauer; Michael Hallek

doi:10.1056/NEJMoa2213093

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

GCLLSG CLL Study Grp
, HOVON CLL Study Grp
, Nordic CLL Study Grp
, Israeli CLL Assoc
, Canc Trials Ireland
, Barbara Eichhorst
, Carsten U. Niemann
, Arnon P. Kater
, Moritz Fuerstenau
, Julia von Tresckow
, Can Zhang
, Sandra Robrecht
, Michael Gregor
, Gunnar Juliusson
, Patrick Thornton
, Philipp B. Staber
, Tamar Tadmor
, Vesa Lindström
, Caspar da Cunha-Bang
, Christof Schneider

Christian B. Poulsen, Thomas Illmer, Bjoern Schoettker, Thomas Noesslinger, Ann Janssens, Ilse Christiansen, Michael Baumann, Henrik Frederiksen, Marjolein van der Klift, Ulrich Jaeger, Maria B. L. Leys, Mels Hoogendoorn, Kourosh Lotfi, Holger Hebart, Tobias Gaska, Harry Koene, Lisbeth Enggaard, Jereon Goede, Josien C. Regelink, Anouk Widmer, Florian Simon, Nisha De Silva, Anna-Maria Fink, Jasmin Bahlo, Kirsten Fischer, Clemens-Martin Wendtner, Karl A. Kreuzer, Matthias Ritgen, Monika Brueggemann, Eugen Tausch, Mark-David Levin, Marinus van Oers, Christian Geisler, Stephan Stilgenbauer, Michael Hallek

Tutkimustuotos: Artikkelijulkaisu › Artikkeli › Tieteellinen › vertaisarvioitu

Alkuperäiskieli	englanti
Lehti	New England Journal of Medicine
Vuosikerta	388
Numero	19
Sivut	1739-1754
Sivumäärä	16
ISSN	0028-4793
DOI - pysyväislinkit	https://doi.org/10.1056/NEJMoa2213093
Tila	Julkaistu - 11 toukok. 2023
OKM-julkaisutyyppi	A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä, vertaisarvioitu

Tieteenalat

Frontline treatment
Obinutuzumab
Ibrutinib
Rituximab
Guidelines
Survival
3122 Syöpätaudit

Pääsy asiakirjaan

10.1056/NEJMoa2213093

Siteeraa tätä

GCLLSG CLL Study Grp, HOVON CLL Study Grp, Nordic CLL Study Grp, Israeli CLL Assoc, Canc Trials Ireland, Eichhorst, B., Niemann, C. U., Kater, A. P., Fuerstenau, M., von Tresckow, J., Zhang, C., Robrecht, S., Gregor, M., Juliusson, G., Thornton, P., Staber, P. B., Tadmor, T., Lindström, V., da Cunha-Bang, C., ... Hallek, M. (2023). First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia. New England Journal of Medicine, 388(19), 1739-1754. https://doi.org/10.1056/NEJMoa2213093

@article{99d085ddde8f47d2b3ff9d97ee0b93c6,

title = "First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia",

keywords = "Frontline treatment, Obinutuzumab, Ibrutinib, Rituximab, Guidelines, Survival, 3122 Cancers",

author = "\{GCLLSG CLL Study Grp\} and \{HOVON CLL Study Grp\} and \{Nordic CLL Study Grp\} and \{Israeli CLL Assoc\} and \{Canc Trials Ireland\} and Barbara Eichhorst and Niemann, \{Carsten U.\} and Kater, \{Arnon P.\} and Moritz Fuerstenau and \{von Tresckow\}, Julia and Can Zhang and Sandra Robrecht and Michael Gregor and Gunnar Juliusson and Patrick Thornton and Staber, \{Philipp B.\} and Tamar Tadmor and Vesa Lindstr{\"o}m and \{da Cunha-Bang\}, Caspar and Christof Schneider and Poulsen, \{Christian B.\} and Thomas Illmer and Bjoern Schoettker and Thomas Noesslinger and Ann Janssens and Ilse Christiansen and Michael Baumann and Henrik Frederiksen and \{van der Klift\}, Marjolein and Ulrich Jaeger and Leys, \{Maria B. L.\} and Mels Hoogendoorn and Kourosh Lotfi and Holger Hebart and Tobias Gaska and Harry Koene and Lisbeth Enggaard and Jereon Goede and Regelink, \{Josien C.\} and Anouk Widmer and Florian Simon and \{De Silva\}, Nisha and Anna-Maria Fink and Jasmin Bahlo and Kirsten Fischer and Clemens-Martin Wendtner and Kreuzer, \{Karl A.\} and Matthias Ritgen and Monika Brueggemann and Eugen Tausch and Mark-David Levin and \{van Oers\}, Marinus and Christian Geisler and Stephan Stilgenbauer and Michael Hallek",

year = "2023",

month = may,

day = "11",

doi = "10.1056/NEJMoa2213093",

language = "English",

volume = "388",

pages = "1739--1754",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "19",

}

GCLLSG CLL Study Grp, HOVON CLL Study Grp, Nordic CLL Study Grp, Israeli CLL Assoc, Canc Trials Ireland, Eichhorst, B, Niemann, CU, Kater, AP, Fuerstenau, M, von Tresckow, J, Zhang, C, Robrecht, S, Gregor, M, Juliusson, G, Thornton, P, Staber, PB, Tadmor, T, Lindström, V, da Cunha-Bang, C, Schneider, C, Poulsen, CB, Illmer, T, Schoettker, B, Noesslinger, T, Janssens, A, Christiansen, I, Baumann, M, Frederiksen, H, van der Klift, M, Jaeger, U, Leys, MBL, Hoogendoorn, M, Lotfi, K, Hebart, H, Gaska, T, Koene, H, Enggaard, L, Goede, J, Regelink, JC, Widmer, A, Simon, F, De Silva, N, Fink, A-M, Bahlo, J, Fischer, K, Wendtner, C-M, Kreuzer, KA, Ritgen, M, Brueggemann, M, Tausch, E, Levin, M-D, van Oers, M, Geisler, C, Stilgenbauer, S & Hallek, M 2023, 'First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia', New England Journal of Medicine, Vuosikerta 388, Nro 19, Sivut 1739-1754. https://doi.org/10.1056/NEJMoa2213093

TY - JOUR

T1 - First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

AU - GCLLSG CLL Study Grp

AU - HOVON CLL Study Grp

AU - Nordic CLL Study Grp

AU - Israeli CLL Assoc

AU - Canc Trials Ireland

AU - Eichhorst, Barbara

AU - Niemann, Carsten U.

AU - Kater, Arnon P.

AU - Fuerstenau, Moritz

AU - von Tresckow, Julia

AU - Zhang, Can

AU - Robrecht, Sandra

AU - Gregor, Michael

AU - Juliusson, Gunnar

AU - Thornton, Patrick

AU - Staber, Philipp B.

AU - Tadmor, Tamar

AU - Lindström, Vesa

AU - da Cunha-Bang, Caspar

AU - Schneider, Christof

AU - Poulsen, Christian B.

AU - Illmer, Thomas

AU - Schoettker, Bjoern

AU - Noesslinger, Thomas

AU - Janssens, Ann

AU - Christiansen, Ilse

AU - Baumann, Michael

AU - Frederiksen, Henrik

AU - van der Klift, Marjolein

AU - Jaeger, Ulrich

AU - Leys, Maria B. L.

AU - Hoogendoorn, Mels

AU - Lotfi, Kourosh

AU - Hebart, Holger

AU - Gaska, Tobias

AU - Koene, Harry

AU - Enggaard, Lisbeth

AU - Goede, Jereon

AU - Regelink, Josien C.

AU - Widmer, Anouk

AU - Simon, Florian

AU - De Silva, Nisha

AU - Fink, Anna-Maria

AU - Bahlo, Jasmin

AU - Fischer, Kirsten

AU - Wendtner, Clemens-Martin

AU - Kreuzer, Karl A.

AU - Ritgen, Matthias

AU - Brueggemann, Monika

AU - Tausch, Eugen

AU - Levin, Mark-David

AU - van Oers, Marinus

AU - Geisler, Christian

AU - Stilgenbauer, Stephan

AU - Hallek, Michael

PY - 2023/5/11

Y1 - 2023/5/11

KW - Frontline treatment

KW - Obinutuzumab

KW - Ibrutinib

KW - Rituximab

KW - Guidelines

KW - Survival

KW - 3122 Cancers

U2 - 10.1056/NEJMoa2213093

DO - 10.1056/NEJMoa2213093

M3 - Article

C2 - 37163621

SN - 0028-4793

VL - 388

SP - 1739

EP - 1754

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 19

ER -